Invivyd, Inc.
HealthcareNASDAQ:IVVD · NASDAQ Global Market
-$0.04 today
Vol 8.34M · Avg 3.40M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.7%
avg -53.7%
ROIC
-22.8%
avg -102.4%
ROA
-19.0%
avg -72.0%
Analysis
ROA is currently the strongest return metric at -19.0% versus its period average of -72.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert D. Allen | Chief Scientific Officer | $828,180.00 | — | 56 | $114,487.00 | 0.09% |
Jill Andersen | Chief Legal Officer & Corporate Secretary | $775,710.00 | — | 53 | $181,736.00 | 0.14% |
William E. Duke Jr. | Chief Financial Officer, Principal Accounting Officer & Principal Executive Officer | $752,777.00 | — | 54 | $107,717.00 | 0.08% |
Timothy Lee | Chief Commercial Officer | $706,866.00 | — | 52 | $117,717.00 | 0.09% |
Julie Green | Chief Human Resources Officer | $542,353.00 | — | 50 | $107,717.00 | 0.08% |
Michael J. Mina | Chief Medical Officer | — | — | 41 | $50,000.00 | 0.04% |
Katie Falzone | Senior Vice President of Finance | — | — | — | — | — |
Kristie Coneys Kuhl | Chief Communications Officer | — | — | — | — | — |
Rachael Gerlach | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$125,000.00
Sells
20
$520,905.78
Net Sentiment
$395,905.78
Net selling
Most Active
Duke William E.
4 transactions
1–10 of 21
Analysis
Insiders reported 1 buys worth $125,000.00 and 20 sells worth $520,905.78 over the last 12 months. That adds up to net selling of $395,905.78. Duke William E. was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +76.7% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +76.7% (6yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.12B
Genfit S.A.
GNFT
$445.68M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$150.58M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Who manages IVVD?
Invivyd, Inc. (IVVD) lists 9 active executives. The top listed executive is Timothy Lee, Chief Commercial Officer.
Are IVVD insiders buying or selling?
Recent insider activity shows net buying of $10.06M.
Explore More
Continue the stock analysis
Jump to another research area for this company.